Holen Sie sich die Stockscreener-App
163.02
0.47%
0.77
Schlusskurs vom Vortag:
$162.25
Offen:
$162.39
24-Stunden-Volumen:
1.14M
Relative Volume:
1.43
Marktkapitalisierung:
$9.72B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
20.35
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+7.26%
1M Leistung:
-4.00%
6M Leistung:
-20.24%
1J Leistung:
-32.38%
1-Tages-Spanne:
$161.30
$165.05
1-Wochen-Bereich:
$151.18
$168.02
52-Wochen-Spanne:
$150.79
$275.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
163.02 | 9.72B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River Laboratories targets $9.10-$9.60 EPS in 2025 amid cost optimization efforts - MSN
William Blair cuts Charles River Labs stock rating to Market Perform - MSN
Charles River Executives Buy Company Stock Amidst Plan Terminations - Investing.com
Charles River Laboratories executive buys $249k in common stock - Investing.com India
Charles River Laboratories executive sells shares worth $715,000 - Investing.com
Recent Transactions by Executives at Charles River Laboratories - TradingView
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories International (NYSE:CRL) Price Target Cut to $173.00 by Analysts at Robert W. Baird - MarketBeat
Charles River Laboratories International Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
New York State Teachers Retirement System Cuts Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Empower Advisory Group LLC Acquires 6,747 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Down 7.4% in January - MarketBeat
Vontobel Holding Ltd. Acquires Shares of 1,817 Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International (NYSE:CRL) Issues FY25 Earnings Guidance - MarketBeat
Stephens Cuts Charles River Laboratories International Price Target to $190 From $240 - Marketscreener.com
Charles River Labs makes good on promise to reduce headcount - The Business Journals
Charles River Laboratories International (NYSE:CRL) Shares Gap Up on Earnings Beat - MarketBeat
Charles River Laboratories International (NYSE:CRL) Posts Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
Charles River Laboratories International (NYSE:CRL) Issues FY 2025 Earnings Guidance - MarketBeat
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $210 From $215, Maintains Buy Rating - Marketscreener.com
JPMorgan Adjusts Price Target on Charles River Laboratories International to $165 From $175, Maintains Neutral Rating - Marketscreener.com
Bryn Mawr Capital Management LLC Acquires 33,850 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River: Q4 Earnings Snapshot - The Pioneer
Charles River Laboratories International Inc (CRL) Q4 2024 Earni - GuruFocus.com
Charles River Laboratories International Inc (CRL) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Charles River Laboratories Reports 2024 Earnings and 2025 Outlook - TipRanks
Charles River Labs stock target cut to $175 by Evercore ISI - Investing.com South Africa
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall - MSN
Charles River Labs Investor Failed to Depict Fraud, Company Says - Bloomberg Law
Narrow-Moat Charles River Faces Macroeconomic Pressures in Near Term; Positive Long-Term Outlook - Morningstar
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance - Benzinga
Q4 Earnings Surpass Expectations For The Andersons And Charles River Laboratories - Evrim Ağacı
Charles River Labs diversifies monkey business in face of political headwinds - The Business Journals
In vitro diagnostics Market Poised for Significant Growth to Reach value of USD 133.24 Billion from 2025 to 2034 - GlobeNewswire Inc.
Evercore ISI Adjusts Charles River Laboratories International Price Target to $175 From $195, Maintains In Line Rating - Marketscreener.com
Earnings call transcript: Charles River Labs Q4 2024 beats EPS forecast - Investing.com
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Charles River Laboratories International (NYSE:CRL) Price Target Lowered to $166.00 at Barclays - MarketBeat
Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4 By Stock Story - Investing.com Canada
Charles River Laboratories International, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2024 - Marketscreener.com
Charles River Laboratories Exceeds Q4 Expectations with $1.00 Billion Revenue and $2.66 Non-GAAP EPS - GuruFocus.com
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by J.P. Marvel Investment Advisors LLC - MarketBeat
Charles River beats quarterly estimates on stable demand for drug development services - Marketscreener.com
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Charles River Laboratories reports Q4 earnings beat, shares edge up By Investing.com - Investing.com Nigeria
Charles River Laboratories reports Q4 earnings beat, shares edge up - Investing.com
Charles River Laboratories Q4 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Charles River Laboratories Q4 Higher Earnings Higher, Revenue Lower; 2025 Guidance Issued - Marketscreener.com
CHARLES RIVER LABS INTL Earnings Results: $CRL Reports Quarterly Earnings - Nasdaq
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
3.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):